The core legal framework

  • Regulations on the Administration of Human Genetic Resources (2019, amended 2024) — the core administrative regulation.
  • Biosecurity Law (2021) — elevating HGR to the level of national biosecurity.
  • Implementation Rules for the HGR Regulations (2023) — operational detail.
  • Personal Information Protection Law (PIPL) — protection of personal data within HGR information.
  • Data Security Law (DSL) — identification and export of "important data".
  • Criminal Law Art. 334-1 — unlawful collection of HGR and smuggling of HGR materials.

Core concepts

The "foreign party" test — a look-through standard

The Implementation Rules adopt a look-through determination of "foreign party" — not just the direct shareholder, but tracing to the actual controller:

  • Foreign-invested enterprises (WFOE/JV) set up in China by foreign organisations or individuals
  • Domestic enterprises in which foreign parties hold more than 50% of equity, voting rights or similar interests
  • Domestic enterprises actually controlled by foreign parties through agreements or other arrangements (e.g. VIE structures)
  • Projects in which foreign parties participate indirectly through their China-established or -controlled entities

Key impact: VIE-structured biotechs, Chinese biotechs controlled by offshore USD funds, and the China subsidiaries of global CROs are all treated as "foreign parties" for HGR purposes. Any collaborative research with domestic hospitals/universities involving HGR therefore requires approval or filing — a compliance trap many early-stage biotechs overlook.

The broad reach of "HGR information"

It is not only "gene sequencing data". The following count as HGR information where they relate to human genetic material:

  • Clinical data (blood counts, biochemistry — reflecting biological characteristics)
  • Imaging data (MRI/CT — often stored alongside other HGR data)
  • Demographic data (where linked to genetic material or information)

In practice: almost any trial with foreign participation that collects patient biosamples or clinical data will likely implicate HGR regulation.

The three-tier system: approval / filing / report

CategoryApplies toAuthority
Approval (prior)① International cooperative research (foreign party + HGR); ② export of HGR materials; ③ collection of important pedigrees / designated resources; ④ preservation of HGR.Ministry of Science & Technology (MOST)
Filing (concurrent)① International cooperative trials at trial sites for marketing approval (without material export); ② providing HGR information to foreign parties.MOST
Prior reportCollection of important pedigree and region-specific HGR — an additional reporting obligation beyond approval.MOST

High-frequency risk scenarios

Scenario 1: central-laboratory testing in an MRCT

A multinational runs a Phase III MRCT in China and sends blood samples to a central lab in Singapore. This is both ① HGR material export (approval required) and ② HGR information export (filing required) when results feed the sponsor's global database.

Scenario 2: a CRO using overseas servers

A domestic company uses a CRO whose EDC system runs on AWS in the US. Even with no foreign sponsor, if data storage or access touches abroad, it is HGR information export — filing required.

Scenario 3: providing China clinical data in a license-out

A Chinese licensor packages China trial data for an overseas licensee. This is HGR information export — filing required, and possibly a security review where volumes are large or sensitive populations are involved.

Consequences of HGR violations

  • Administrative: suspension/termination of projects, revocation of approvals, confiscation of resources and proceeds, fines of CNY 500,000–5,000,000 (or 5–10× unlawful gains above CNY 1,000,000), and a record of serious research-integrity breach.
  • Criminal: Criminal Law Art. 334-1 — up to 3 years for serious cases, 3–7 years for especially serious cases, plus fines.
  • Commercial: trial suspension delays R&D (threatening deal timelines) and attracts scrutiny in IPO reviews.

How we help

  1. HGR assessment: pre-trial evaluation of whether a project implicates HGR, foreign-party status, and approval vs. filing.
  2. Applications: preparing and submitting approval/filing materials and tracking progress with MOST.
  3. Counterparty screening: reviewing CROs, central labs and data managers for HGR compliance background.
  4. Cross-border planning: choosing the approval/filing/security-review route and preparing standard contractual clauses.
  5. Enforcement response: self-inspection and remediation during MOST special inspections.